^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

DRD2 antagonist

1d
Ubiquitin-Specific Proteases in Breast Cancer: Unraveling Oncogenic Roles and Therapeutic Opportunities. (PubMed, DNA Cell Biol)
Pharmacological inhibitors of specific USPs, such as pimozide, trifluoperazine, rottlerin, 6-thioguanine, and costunolide, are highlighted for their potential to inhibit proliferation, metastasis, induce apoptosis, and circumvent therapy resistance across breast cancer subtypes (triple-negative and HER-2 positive). The review highlights the complex and often contradictory roles of USPs in breast cancer and points to the immense promise of targeting these enzymes to develop new and efficacious anticancer therapies.
Review • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive
|
thioguanine
3d
Selected Disorders and Sleep Bruxism (clinicaltrials.gov)
P=N/A, N=100, Enrolling by invitation, Wroclaw Medical University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
Trial completion date • Trial primary completion date
3d
Chlorpromazine inhibits EAG1 channels by altering the interdomain coupling. (PubMed, Biophys J)
This further suggests that if chlorpromazine binding alters coupling between the PAS/CNBH domain ring, VSD and pore, as predicted by the network analysis, these alterations occur at potential more depolarized than the ones eliciting the Cole-Moore shift. Taken together, our study provides an insight into the allosteric pathways of EAG1 channel regulation by small molecule PAS domain binders.
Journal
|
SPR (Sepiapterin Reductase)
|
chlorpromazine
5d
Chlorpromazine activates cGAS-STING signaling and reprograms the immune response in glioblastoma. (PubMed, Front Immunol)
We demonstrate that CPZ, alone or in combination with temozolomide (TMZ), the current standard of care, activates the cGAS-STING signaling pathway, thus promoting anti-tumor immune responses. This study uncovers that CPZ exerts a previously unrecognized anti-cancer immunomodulatory activity, remodeling the immune microenvironment and enhancing the anti-tumor immune response. By overcoming TMZ resistance, CPZ not only exerts a direct anti-neoplastic effect, but also sensitizes GBM cells to standard therapy.
Journal • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
temozolomide • chlorpromazine
5d
New P4 trial • Head-to-Head
5d
Olanzapine Plus Metoclopramide for the Prevention of Opioid-Induced Nausea and Vomiting (clinicaltrials.gov)
P3, N=222, Recruiting, Affiliated Hospital of Qinghai University | Initiation date: Sep 2025 --> Feb 2026
Trial initiation date
|
olanzapine
10d
Multiple endocrine neoplasia with an atypical clinical course and a MEN1 gene variant of uncertain pathogenicity: A case report. (PubMed, Medicine (Baltimore))
This case underscores the importance of considering MEN1 even in elderly patients with atypical manifestations, emphasizes the value of integrating prior medical history into diagnosis, and suggests a potential role of rs2959656 in MEN1 pathogenesis.
Journal
|
MEN1 (Menin 1)
10d
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma (clinicaltrials.gov)
P2, N=90, Recruiting, Jazz Pharmaceuticals | Not yet recruiting --> Recruiting
Enrollment open
|
JZP3507
11d
Clozapine Mitigates Lipopolysaccharide-Induced Cognitive Dysfunction by Modulating Cholinergic Function, Oxidative Stress, and Apoptotic Signaling in Rats. (PubMed, Life (Basel))
The findings demonstrate that CLZ exerts neuroprotective effects in an LPS-induced rat model, improving cognition through modulation of cholinergic transmission, oxidative stress, and apoptosis pathways. These results clarify key mechanistic pathways through which CLZ may exert cognitive benefits and highlight its potential relevance for improving schizophrenia-related cognitive dysfunction. Further molecular studies are warranted to confirm and extend these observations toward clinical translation.
Preclinical • Journal • IO biomarker
|
BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • CAT (Catalase)
11d
Pimozide Reprograms the Ran GTPase-SCF Axis and Matrix Remodeling Pathways in Breast, Colorectal, and Pancreatic Cancer Models. (PubMed, Cancers (Basel))
Pimozide exerts anticancer effects through coordinated disruption of nucleocytoplasmic transport, proteostasis regulation, and matrix remodeling. These findings support the repositioning of pimozide as a multi-target anticancer agent and provide a mechanistic foundation for further translational investigation.
Preclinical • Journal
|
MMP2 (Matrix metallopeptidase 2) • CUL1 (Cullin 1) • SKP2 (S-phase kinase-associated protein 2)
11d
Redefining Pituitary Neuroendocrine Tumors in MEN1: Prevalence, Clinical Behavior, and Implications for Long-Term Surveillance. (PubMed, Curr Oncol)
In our MEN1 cohort, PitNETs were frequent but largely indolent, with a predominance of microadenomas and limited need for surgery. Our findings support individualized, subtype-driven surveillance strategies, with conservative management for clinically non-functioning microadenomas and closer monitoring of prolactin-secreting PitNETs due to variable medical responsiveness.
Journal
|
MEN1 (Menin 1)
12d
An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine (clinicaltrials.gov)
P4, N=5, Terminated, Ohio State University | N=60 --> 5 | Trial completion date: Jun 2026 --> Jan 2026 | Recruiting --> Terminated; Not able to recruit enough subjects
Enrollment change • Trial completion date • Trial termination
|
olanzapine